Tempus AI has skyrocketed 21% in the last three ... outperformed other players in the health infotech field like iRhythm Technologies and SOPHiA GENETICS, which have risen 4.1% and 10.1% ...

Gifting allows recipients to access the article for free. Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock followed the announcement of a multiyear collaboration ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

Stocks recently featured in the blog include: Tempus AI TEM, AstraZeneca AZN, iRhythm Technologies IRTC and SOPHiA GENETICS SOPH. Here are highlights from Thursday’s Analyst Blog: Tempus AI ...

BTIG notes that shares of Tempus AI (TEM) are up on news that the company signed a $200M expanded strategic agreement with AstraZeneca (AZN) and Pathos AI, where the three companies will ...

"Fabrinet is thrilled to support Innoviz in reaching this significant milestone of mass-producing the InnovizTwo and industrializing the Company's cutting-edge LiDAR technology," said Harpal Gill ...

April 25 (Reuters) - India's Tata Technologies (TATE.NS), opens new tab reported a smaller-than-expected revenue for the fourth quarter, hurt by slowing global demand for electric vehicles.

As the technology matures, BCIs are becoming central to efforts aimed at restoring autonomy in individuals affected by neurological injuries and diseases. These systems translate neural activity ...